Daiichi Sankyo (DSNKY) News Today $28.99 +2.22 (+8.29%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer DrugJanuary 20 at 2:00 AM | marketwatch.comFDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast CancerJanuary 18 at 7:58 AM | markets.businessinsider.comDaiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mJanuary 15, 2025 | msn.comDaiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbHJanuary 13, 2025 | uk.finance.yahoo.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Growth in Short InterestDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 54,800 shares, a growth of 896.4% from the December 15th total of 5,500 shares. Based on an average trading volume of 573,800 shares, the days-to-cover ratio is presently 0.1 days.January 13, 2025 | marketbeat.comDatopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13, 2025 | finance.yahoo.comHigh Expectations And Data Disappointments Have Driven Daiichi Sankyo LowerJanuary 10, 2025 | seekingalpha.comDaiichi Sankyo gets Japanese approval for DatrowayDecember 28, 2024 | msn.comAstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EUDecember 24, 2024 | markets.businessinsider.comAstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EUDecember 24, 2024 | marketwatch.comAstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab DeruxtecanDecember 24, 2024 | markets.businessinsider.comDaiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third timeNovember 20, 2024 | msn.comDaiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy RatingNovember 13, 2024 | markets.businessinsider.comDaiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOSNovember 13, 2024 | finance.yahoo.comAstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecanNovember 12, 2024 | markets.businessinsider.comAlteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ TechnologyNovember 10, 2024 | finance.yahoo.comAlteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU DevelopmentNovember 10, 2024 | markets.businessinsider.comENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology ProductNovember 8, 2024 | finance.yahoo.comBernstein Reaffirms Their Buy Rating on Daiichi Sankyo Company (DSKYF)November 1, 2024 | markets.businessinsider.comThree Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerOctober 30, 2024 | finance.yahoo.comDaiichi Sankyo to Boost ADC Cancer Drug Production, COO SaysOctober 10, 2024 | bloomberg.comDaiichi Sankyo Co (OTC:DSNKY) Stock Quotes, Forecast and News SummarySeptember 18, 2024 | benzinga.comDaiichi Sankyo: Showing No Signs Of Slowing Down ADC DominanceSeptember 18, 2024 | seekingalpha.comDaiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 StudySeptember 17, 2024 | markets.businessinsider.comAstraZeneca, Roche cut at Deutsche after trial readouts for key drugsSeptember 13, 2024 | seekingalpha.comIs Merck Stock Undervalued After Its Colossal Earnings Growth? (DSNKY)Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?September 13, 2024 | marketbeat.comAstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming DataSeptember 12, 2024 | seekingalpha.comDaiichi Sankyo Plunges on Mixed Trial Result of Lung Cancer DrugSeptember 10, 2024 | bloomberg.comMerck, Daiichi post mid-stage data for novel lung cancer drugSeptember 7, 2024 | msn.comENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast CancerAugust 19, 2024 | finance.yahoo.comDSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024August 13, 2024 | investorplace.comMerck, Daiichi Sankyo Add Merck's MK-6070 to CollaborationAugust 6, 2024 | marketwatch.comMerck, Daiichi Sankyo expand cancer drug dealAugust 6, 2024 | msn.comDaiichi Sankyo Co Ltd ADR (DSNKY)August 5, 2024 | in.investing.comHere's what Wall Street expects from DAIICHI SANKYO's earnings reportJuly 30, 2024 | markets.businessinsider.comDaiichi Sankyo Opens New Affiliate for Oncology in GreeceJuly 10, 2024 | businesswire.comAstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in PatientsMay 27, 2024 | marketwatch.comDaiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCOMay 21, 2024 | finance.yahoo.comHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock SoarsMay 7, 2024 | finance.yahoo.comDSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023April 30, 2024 | investorplace.comAstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival ImprovementApril 29, 2024 | finance.yahoo.comMHRA authorises Daiichi Sankyo quizartinib for AML for marketingMarch 13, 2024 | msn.comPfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugatesMarch 2, 2024 | msn.comDaiichi Sankyo Co. Ltd. ADRFebruary 25, 2024 | wsj.comDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerFebruary 19, 2024 | finance.yahoo.comDaiichi Sankyo Co Ltd 4568February 16, 2024 | morningstar.comDaiichi invests 1 billion eur near Munich to make precision cancer drugsFebruary 16, 2024 | news.yahoo.comDaiichi invests 1 bln eur near Munich to make precision cancer drugsFebruary 16, 2024 | finance.yahoo.comQ4 2023 Merck & Co Inc Earnings CallFebruary 2, 2024 | finance.yahoo.comWhat's Going On With Pfizer Stock Today?January 25, 2024 | msn.com Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Media Mentions By Week DSNKY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSNKY News Sentiment▼0.640.63▲Average Medical News Sentiment DSNKY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSNKY Articles This Week▼30▲DSNKY Articles Average Week Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sanofi News Today GSK News Today Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Genmab A/S News Today Viatris News Today Genmab A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:DSNKY) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
